Wall Street Journal Discusses New Sleep Drug with NeuroTrials CEO Dr. Russell Rosenberg

June 25, 2013

rosenbergThe Wall Street Journal discussed the new insomnia sleep drug, suvorexant, scheduled to hit shelves in the coming months with NeuroTrials CEO & Chair of the National Sleep Foundation, Dr. Russell Rosenberg.

An estimated 25% or more Americans face a bout of insomnia in a given year, and at least 1 in 10 suffers the chronic form of the disorder, routinely facing sleepless nights, according to the Centers for Disease Control and Prevention.

“There’s a need for more drugs,” said Russell Rosenberg, chairman of the National Sleep Foundation. Current drugs don’t work for everyone, and a push to lower doses amid safety concerns has led to patients “coming in and saying it’s not working as well,” said Dr. Rosenberg..

To read the full article, click here.

Advertisements

Join the Search To End Alzheimer’s Disease

June 20, 2013

alz

NeuroTrials Research is conducting a 26-week, placebo-controlled research study on the safety & efficacy of an investigational drug for Alzheimer’s disease.

Alzheimer’s disease was first identified more than 100 years ago, but research into its symptoms, causes, risk factors and treatment has gained momentum only in the last 30 years. Although research has revealed a great deal about Alzheimer’s, the precise changes in the brain that trigger the development of Alzheimer’s, and the order in which they occur, largely remain unknown.

We need your help enrolling for the latest Alzheimer’s clinical trial!

What’s different about this trial?

  1. Participants can stay on all current prescribed Alzheimer’s treatments. No need to wash out or make the difficult choice to remove your loved one from their current mediation.
  2. Open label option after the initial 26 weeks of study drug /placebo. All participates who complete the initial 26 weeks of the study will have the option to continue in the open label study where they will receive study drug (no placebo) for an additional 26 weeks.

Study-related care and study drug will be provided at no cost. Qualified participants and caregivers or study partner will be compensated for time and travel.

How do I qualify?

To qualify, participants must:

  • be 66-90 years old
  • have a diagnosis of mild to moderate Alzheimer’s disease
  • have a study partner capable of attending all study visits
  • otherwise be in good general health.

How can I learn more?

Click here to visit the study page to fill out a contact form, or contact us directly at 404-851-9934.
We also have new research studies opening up throughout the year. For more information about our studies, or to be included in our patient database for future studies, please contact us at (404) 851-9934, or visit us at www.neurotrials.com.


Over One Million Americans Suffer From Binge Eating Disorder

January 10, 2013

Binge eating

 

Binge Eating Disorder(BED) is the most common eating disorder and can have serious health implications for those diagnosed with the condition.

 

Over one million Americans suffer from BED. Consult our checklist below:

  • Do you eat an amount of food that is definitely larger than most people would eat in a small period of time? (i.e. within 2 hours?)
  • Do you feel a lack of control over how much you eat?
  • Do you eat more rapidly than normal?
  • Do you always eat until you are uncomfortably full?
  • Do you eat large amounts of food even when you do not feel hungry?
  • Are you embarrassed to eat around others because of how much you eat?
  • After eating, do you feel disgusted, depressed, or guilty?
  • Do you binge eat even though you are not bulimic or anorexic?

 If you answered yes to a majority of these questions, you may have BED.

For more information on BED  & to learn about current NeuroTrials studies, please call 404-851-9934 or visit www.neurotrials.com.

You can also follow us on Twitter & Facebook for real-time updates and research study news.


Writhing and Rolling from Restless Legs? Learn About the Sleep Disorder & New Research.

October 29, 2012

Restless legs syndrome (RLS) is a condition in which your legs feel extremely uncomfortable, usually while you’re sitting or lying down. Essentially, it makes you feel like getting up and moving around. Once you start moving, the unpleasant feeling of restless legs syndrome temporarily goes away.

Restless legs syndrome doesn’t discriminate- it can begin at any age and it generally worsens as you get older. While many suspect the condition may be due to an imbalance of the brain chemical dopamine or iron deficiency, no specific cause for all cases of restless legs syndrome exists. Researchers have found that RLS runs in families in up to half of all cases.

If you happen to suffer from RLS, learn about our new research study below.

New RLS Research Study

This is a 14 week, 9 office visit study to examine the safety and efficacy of an investigational drug for Restless Legs Syndrome. Compensation is available for the patient.

Qualifying Criteria

  • Age 18-70
  • Have a history of RLS for over 6 months
  • Experience symptoms of RLS at least 15 nights per month
  • Good general health with no unstable conditions

To learn more about this study, visit our study page.

We also have new research studies opening up throughout the year.  For more information about our studies, or to be included in our patient database for future studies, please contact us at (404) 851-9934, or visit us at www.neurotrials.com.


NeuroTrials Crew Mucking In for MS Research!

September 27, 2012

Katy McNulty is the Outreach Coordinator for NeuroTrials Research. Katy will be guest posting on the NeuroTrials blog, providing readers with a closer look into what it means to participate in the clinical research community.

Next Saturday, October 6, a brave crew of NeuroTrials’ finest will be getting down and dirty at the National Multiple Sclerosis Society’s Muck Ruckus Event to help raise awareness about MS research. The 5 mile trail race at Serenbe is peppered with challenges like crawling through the mud under barbed wire, climbing over crazy structures, and swinging on a rope over a pool of muddy water. It’s not for the timid!

How did we get into this? It seemed only natural! NeuroTrials has been “in the muck” of MS research (along with other neurological and sleep research) for more than 15 years. We were excited about the opportunity to honor the individuals who support and participate in MS research by literally getting in the muck ourselves.

We’ll be representing NeuroTrials as team “Research and Destroy.” We’ll be cheered on by a great team of co-workers who are manning a booth with information about MS research. They’ll have giveaways and candy as well, so be sure to stop by the tent and say hello!

Let me introduce you to the members of team Research & Destroy:

Shanna, our office manager, has been an athlete all her life. She’s been playing competitive basketball and soccer ever since she can remember… and hasn’t slowed down yet. Anyone who knows Shanna can tell you she’s not someone you want to tangle with! Her Yankee-fierceness and tenacity make her someone I’m grateful to have on my side. However, she’s never been a big runner. When she heard the course length, she said “5 miles!?!? Are you kidding me? I’ve never run 5 miles in my life! I practice sprinting for soccer, but I don’t do distance!” Don’t worry… she’s been adding runs to her workout regimen and something tells me she’s going to be just fine! I’ll be sure to stay out of her way.

 

Keir is a good friend from FusionSleep. She’s lively, fun and a natural team player who is not afraid to get dirty! Keir played some basketball in high school, but never considered herself an athlete. She started running about 3 years ago when she realized she was getting older and she “didn’t want to be one of those older people who can’t do anything.” Through exercise and lifestyle changes, she transformed herself and her body. So far, her greatest running distance is 10k and she’s training for a 15k in January. She says she’s not the fastest runner, but she’ll get there. Her slogan for this event is “Keir will bring up the rear”. But Keir’s transformative history leads me to believe that she might surprise herself once she’s in the muck for a good cause.

 

My own fitness history is varied and sundry. Growing up, I was always the tallest girl around and was constantly being asked about joining local basketball or volleyball teams – until they’d see me play. Then they’d stop asking! I practiced some yoga as an adult, but was otherwise sedentary and a firm believer in not running unless I was being chased. I started running 2 years ago after a few friends talked me into signing up for a Warrior Dash – a 5k trail/mud run with obstacles. Sound familiar? It looked like so much fun! I wasn’t afraid of mud, but I knew I would have to take up running so I wouldn’t look like a complete idiot on the course. I slowly trained and had a blast! Somewhere in there I learned to like running and went on to complete my first half marathon last March. A few months ago, I started doing Crossfit and I’m hoping the tough cross-training will come in handy for these obstacles. I’m excited to get in the mud again and for such a great cause!

If anyone would like to join team Research & Destroy, click the link to our team page and sign up! We are competing in the 10am recreational wave. http://main.nationalmssociety.org/site/TR?pg=team&fr_id=18833&team_id=306309

If you’d rather stay out of the muck, we welcome you to make a donation on our team page or come out and cheer us on. Serenbe is a fabulous venue! You can safely watch from the viewing areas, grab some lunch, visit the NeuroTrials booth, enjoy some family entertainment, and participate in a great cause.

For more information about our Multiple Sclerosis research study, click here: http://www.atlantasleep.com/msresearch-0/ or call (404) 851-9934. 


Dr. Rosenberg Appears on NPR “Morning Edition”

August 27, 2012

NeuroTrials Research & Atlanta School of Sleep Medicine CEO Dr. Russell Rosenberg joined the NPR Morning Edition show today to discuss sleepwalkers. An excerpt from the interview is below:

Though a sleepwalker’s brain might be partially awake, most sleepwalkers have no memory of their episodes, and that’s a key feature, says Russell Rosenberg, chairman of the National Sleep Foundation and CEO of Neural Trials Research in Atlanta. Some research suggests that the sleepwalker’s frontal cortex — the brain’s center for decision-making, judgment and short-term memory — is not fully online during sleepwalking.

For the full transcript of the interview or to listen online, click here.


New Finding Could Lead to New Therapy for Multiple Sclerosis

August 1, 2012

Researchers at the Wayne State University School of Medicine, working with colleagues in Canada, have found that one or more substances produced by a type of immune cell in people with multiple sclerosis (MS) may play a role in the disease’s progression. The finding could lead to new targeted therapies for MS treatment.

B cells, said Robert Lisak, M.D., professor of neurology at Wayne State and lead author of the study, are a subset of lymphocytes (a type of circulating white blood cell) that mature to become plasma cells and produce proteins that serve as antibodies.

In patients with MS, the B cells seem to attack the brain and spinal cord. Researchers believe that there might be substances produced in the nervous system and the covering of the brain and spinal cord that attract the cells. Once the B cells are inside the central nervous system or brain, the cells secrete substances that damage the cells that produce protections.

“We think this is a very significant finding, particularly for the damage to the cerebral cortex seen in patients with MS, because those areas seem to be damaged by material spreading into the brain from the meninges, which are rich in B cells adjacent to the areas of brain damage,” Lisak said.

Do you have MS? NeuroTrials Research is conducting a research study to determine the efficacy of an investigational drug. Qualified participants receive all study-related exams and study drug at no cost. Compensation is available for time and travel. For more information, visit the study page or call us at 404-538-9284.